



Citation for published version:

Sammon, CJ, Charlton, RA, Snowball, J & Weil, JG 2015, 'The incidence of childhood and adolescent seizures in the UK from 1999 to 2011: a retrospective cohort study using the Clinical Practice Research Datalink', *Vaccine*, vol. 33, no. 51, pp. 7364-7369. <https://doi.org/10.1016/j.vaccine.2015.07.093>

DOI:

[10.1016/j.vaccine.2015.07.093](https://doi.org/10.1016/j.vaccine.2015.07.093)

Publication date:

2015

Document Version

Peer reviewed version

[Link to publication](#)

University of Bath

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

1 **The incidence of childhood and adolescent seizures in the UK from 1999 to 2011; a retrospective**
2 **cohort study using the Clinical Practice Research Datalink**

3 **Cormac J Sammon, Rachel A Charlton, Julia Snowball, John G Weil**
4

5 1. **Cormac J Sammon** (Corresponding author)

6 University of Bath,

7 Claverton Down,

8 Bath, BA2 7AY,

9 UK

10 C.Sammon@bath.ac.uk

11

12

13 2. **Rachel A Charlton**

14 University of Bath,

15 Claverton Down,

16 Bath, BA2 7AY,

17 UK

18 R.A.Charlton@bath.ac.uk

19 3. **Julia Snowball**

20 University of Bath,

21 Claverton Down,

22 Bath, BA2 7AY,

23 UK

24 J.Snowball@bath.ac.uk

25 4. **John G Weil**

26 ,

27 Novartis Vaccines and Diagnostics,

28 Hullenbergweg 83

29 Amsterdam,

30 Netherlands

31 john.weil@novartis.com

32

33 **Keywords:** Vaccines, Seizures, General Practice, Incidence, Epidemiology

34 **Word count:**

35 Abstract 265/300

36 Full text: 2738/3000

37 Tables/Figures: 6/6

38 **Background**

39 In postmarketing vaccine surveillance, adverse events observed in a vaccinated population are
40 compared to the number expected based on a background incidence rate. The background rate should
41 be accurate and obtained from a population comparable to the one vaccinated. Such rates are often
42 not available.

43 **Methods**

44 The incidence rate of generalised convulsive, febrile and afebrile seizures was estimated in individuals
45 born after 01-January-1998 and aged between 2 months and 15 years of age using the UK Clinical
46 Practice Research Datalink (1999-2011).

47 **Results**

48 The study population consisted of 1,532,992 individuals (4,917,369 person years (PY) of follow up). A
49 total of 28,917 generalised convulsive seizure events were identified during follow-up, the overall
50 incidence rate was 5.88 per 1,000PY. Age specific rates increased sharply from 4/1,000PY at 2 months
51 of age, peaked at 19/1,000PY at 16 months and decreased until approximately 6 years of age at which
52 point they became relatively stable at 2/1,000PY. 67% of GCSs were categorised as febrile: 56% using
53 Read codes, 11% using free text. Febrile seizures accounted for the age trend in GCS, with rates
54 peaking at 16.1/1,000PY at 16 months of age while afebrile seizure rates remained relatively stable
55 across all ages (24 seizures per 1,000PY). Analysis by first occurrence of febrile seizure showed a similar
56 pattern, comparable to published studies on the incidence of seizures in childhood.

57 **Discussion**

58 The rates reported in this study could be used in the postmarketing surveillance of infant vaccines.
59 However, given the variation across strata, and the potential underascertainment of seizure events
60 presenting to A&E, care must be taken when interpreting and using these rates.

61 **Background**

62 Generalised convulsive seizures (GCS) are episodes of neuronal hyperactivity resulting in involuntary
63 muscle contraction and impairment or loss of consciousness. [1]. GCS can result from known causes
64 such as epilepsy syndromes, central nervous system infections and acute electrolyte imbalances,
65 however most remain idiopathic [2].

66 Febrile seizures (FS) are a particular type of idiopathic GCS in which seizure onset is preceded by a
67 fever [3]. They are the most common type of seizure with up to 5% of the population suffering at least
68 one FS before 5 years of age [4-6]. The incidence of febrile seizures is highest between 6 and 36 months
69 of age and has been shown to peak at approximately 18 months of age [7]. Approximately one third
70 of individuals who have a febrile seizure will suffer a recurrence, with family history, lower peak
71 temperature of fever, short duration of fever and febrile seizures in young individuals being associated
72 with a greater risk of recurrence [8, 9].

73 A number of vaccines have been linked with an increased risk of febrile seizure, most notably the
74 measles, mumps and rubella (MMR) vaccine [10], the whole cell pertussis (DTP) vaccine [11] and the
75 CSL pandemic (H1N1) influenza vaccine [12]. As a result, (febrile) seizures are commonly prioritised
76 for close surveillance in vaccine safety monitoring.

77 Prior to the 2009 pandemic vaccination campaign Black *et al* highlighted the importance of
78 background incidence rates, in vaccine surveillance [13]. They illustrated how such rates can be used
79 as an expected rate against which the rates observed in a vaccinated population could be compared.
80 They also underlined the need to be aware of any geographic, ethnic and age differences in such rates
81 and their dependence on the method used to develop the rates. Examples of their use during the 2009
82 pandemic can be found in the literature [14, 15]. Background incidence rates of GCS for the United
83 Kingdom are not widely available in the published literature [4, 16] and they lack the appropriate level
84 of stratification for use in an infant vaccine programme. This study seeks to investigate the incidence
85 of GCS in infants, children and adolescents in the UK Clinical Practice Research Datalink (CPRD) and to
86 determine whether the CPRD can accurately categorise GCS by distinguishing FS from afebrile GCS.

87 **Methods**

88 This study was carried out using the UK Clinical Practice Research Datalink (CPRD). The CPRD is an
89 electronic healthcare database containing the anonymised primary care medical records of ~8.4% of
90 the UK general population. Patient data routinely collected in primary care and therefore available in
91 the database include demographic details, diagnoses and symptoms including those leading to
92 hospital admissions, immunisations, pregnancies, laboratory tests, referrals to specialists,
93 prescriptions issued by the general practitioner (GP, primary care physician) and deaths [17, 18]. In
94 the UK a patient's primary care record is considered their main electronic health record therefore
95 events occurring in secondary care (e.g. emergency room visits, hospital inpatient events) should be
96 reported to a patient's GP and entered into their record. Despite this, recording of secondary care
97 data in the primary care record is incomplete. Clinical events in the CPRD are recorded using clinical
98 codes known as a Read codes. There are currently over 100,000 Read codes each of which is associated
99 with a short description of varying specificity. Diagnostic Read codes can be considered equivalent to
100 ICD codes, with many mapping directly to specific ICD codes, however a range of additional Read codes
101 exist to facilitate the complexities of patient management in primary care. In order to further facilitate
102 the management of patients in primary care, recording of additional, unstructured textual information
103 in association with a Read code is also possible. This information, commonly referred to as 'free text',
104 generally contains elaborations on the information in the coded record.

105 The study period ran from 01-January-1999 to the 31-December-2011. The study population
106 comprised individuals permanently registered in the CPRD and aged between 2 and 180 months (15
107 years) at some point during the study period. Follow up of each patient began at the start of the study
108 period, an age of 2 months or the date of registration with the CPRD, whichever was latest. Follow up
109 ended at the end of the study period, an age of 180 months, date of death or transfer out of the GP
110 practice, whichever is earliest.

111 In the CPRD the month of birth is only available for individuals aged less than 15 years old. Individuals
112 born before the 01-January-1998 had reached the age of 15 before the end of the study period and
113 therefore did not have a record of their month of birth available. Individuals were therefore excluded
114 from the study population if they were born before 01-January-1998.

115 Our definition of GCS generally followed the Brighton Collaboration definition [1] in that it sought to
116 include all convulsive seizures regardless of their cause and nature. Primary care data, such as that
117 contained in the CPRD, is often unsuited to classification of cases at specific Brighton collaboration
118 classification levels as data on many of the necessary classification criteria are not commonly recorded
119 in general practice. As a result we did not attempt to define cases at specific Brighton collaboration
120 classification levels. Operationally, GCS events were therefore identified as any event recorded against
121 one of the seizure related Read codes listed in tables A1.1, A1.2 or A1.3 in supplementary file 1.

122 We sought to separate GCS events into those that were febrile and afebrile. Two clinical definitions of
123 febrile seizure can be found in the published literature [3, 19]. Both of these define a febrile seizure
124 as a seizure which is associated with a fever and occurs in an individual aged less than 5 years old with
125 no central nervous system infections and with no history of afebrile seizure. The primary difference
126 between these two definitions is the minimum age at which they determine a seizure can be defined
127 as febrile (1 vs. 3 months). Taking both the nature of CPRD data and these clinical definitions of febrile
128 seizures into account, in this study a febrile seizure was defined as any seizure occurring in association
129 with a fever in an individual: aged greater than 1 month old, with no evidence of central nervous
130 system infection and with no history of epilepsy. Note that the exclusion of *all* individuals with a
131 history of afebrile seizure was not included in this definition as the sensitivity of such an exclusion
132 criterion in the CPRD is likely to be poor. Operationally, febrile seizures meeting this definition were
133 identified in the CPRD using (a) a code for febrile seizure, (b) a code for seizure and a code for fever or
134 febrile seizure recorded within 2 weeks either side (c) a code for seizure and a free text entry indicating
135 a fever was present. In line with our clinical definition of febrile seizure, events identified under

136 definitions (a), (b) and (c) were not considered febrile if central nervous system infections were
137 recorded in the patient's record in the 2 weeks before or 6 weeks after the event or if an epilepsy code
138 was recorded anywhere prior to the event. The codes defining such events are provided in Table A1.5
139 and Table A1.6 of supplementary file 1.

140 All GCS events that did not meet the above definition of a febrile seizure were considered afebrile
141 seizure events.

142 The total number of GCS events in age, sex and calendar year specific periods were calculated and
143 used as the numerators in the stratified incidence rates. The amount of person-time contributed by
144 the study population in each age, sex and calendar year specific period was calculated and used as the
145 denominator in the stratified incidence rates. Unless otherwise specified, all incidence rates were
146 reported as numbers of seizures per 1,000 person years (PY). Confidence intervals were estimated
147 assuming a normal binomial distribution for all rates. As per CPRD policy, strata with <5 events are
148 reported as <5 and no incidence rates were calculated. Rates of afebrile and febrile seizures were
149 calculated using the same method. In addition, rates of *first* GCS, febrile and afebrile seizure were
150 estimated by including only the first event per individual in the numerator and censoring follow up for
151 the denominator at first seizure occurrence. The total number of events and the number of first events
152 that could be expected in given time periods after vaccination of a hypothetical cohort of children was
153 also calculated by multiplying the incidence rates by the parameters describing the hypothetical
154 population.

156 **Results**

157 The study population consisted of 1,173,916 individuals who contributed 4,917,369 person years of
158 follow up during the study period. A total of 28,917 GCS events were identified during follow-up
159 providing an overall incidence rate of GCS in the entire study population of 5.88 per 1,000 PY. Figure
160 1 and Table 1 show age specific incidence rates of GCS. Rates increased sharply from 3.5/1,000 PY at

161 2 months of age, peaked at 19.2/1,000 PY at 16 months and decreased until approximately 6 years of
162 age at which point they became relatively stable at approximately 2/1,000 PY. The incidence rate for
163 those aged between 2 months and 5 years was 8.99 per 1,000 PY.

164 No meaningful differences were observed between the sex specific rates of GCS (data not shown).
165 Table A2.1 (Supplementary file 2) shows the age category specific incidence of GCS across calendar
166 years. The distribution by age was similar within calendar years. However, rates decreased slightly
167 over time.

168 There were 19,622 febrile seizure events and 9,295 afebrile seizure events resulting in overall
169 incidence rates of 4.01 and 1.89 seizures per 1,000 PY respectively. Figure 1 and Table 1 compare age
170 specific incidence rates of febrile, afebrile and generalised convulsive seizure. The rate of afebrile
171 seizure remained stable across ages (2-4 seizures per 1,000 person years). In contrast, febrile seizure
172 rates account for the peak in the GCS incidence rate at 18 months and the general trend observed up
173 to 6 years. After 5 years of age the rate of febrile seizures is lower than that of afebrile. The incidence
174 rate for those aged between 2 months and 5 years was 6.68 per 1,000 PY for febrile seizure and 2.32
175 per 1,000 PY for afebrile seizure. No meaningful sex distribution was observed for febrile/afebrile
176 seizure (data not shown). Table 3 describes the proportion of febrile seizures that were identified
177 using each of the three case identification methods.

178 When the analysis was restricted to *first* events 18,336 GCS events were identified during 4,837,363
179 person years of follow up, 14,015 febrile seizure events were identified during 4,839,251 person years
180 of follow up and 5,447 afebrile seizure events were identified during 4,895,611 person years of follow
181 up. This resulted in overall incidence rates of 3.79, 2.90 and 1.11 seizures per 1,000 PY respectively.
182 Figure 2 and Table 2 show age specific incidence rates of first febrile, afebrile and generalised
183 convulsive seizure. While the age specific rates of first seizure are unsurprisingly lower than those for
184 all seizures, the distribution across age categories is similar to that for all seizures. Gender and year

185 specific rates of first seizure showed similar distributions to rates for all events (Table A2.2,
186 supplementary file 2).

187 Supplementary file 3 contains interactive tables which can be used to obtain the incidence rates and
188 expected numbers of first/all febrile, afebrile or generalised convulsive seizure events for reader-
189 defined age, sex and calendar year stratum, in addition the reader can alter the number of individuals
190 vaccinated and the duration of surveillance.

191

192 **Discussion**

193 This study reports month of age specific incidence rates of generalised convulsive, febrile and afebrile
194 seizures for children and adolescents in the CPRD, the incidence rates can be used to calculate the
195 expected numbers of seizures in an infant childhood vaccination programme.

196 The analysis by first occurrence of GCS was included to compare the results for the categorisation of
197 febrile and afebrile seizures with the literature [5, 20]. The pattern is similar with FS less common than
198 afebrile seizures in the first few months of life , increasing thereafter to reach a peak in the second
199 year of life, then dropping sharply from the third year of life to become less frequent than afebrile
200 seizures after four or five years of age. The results suggest the CPRD can reliably identify FS. Our use
201 of diagnostic codes associated with fever identified 4% of FS, while our use of free text strings
202 associated with fever identified 16% of FS (Table 3). While we have not validated the febrile nature of
203 seizures identified using each of the methods we believe that similar approaches should be considered
204 when seeking to distinguish febrile seizures from afebrile seizures on the CPRD. If specificity were
205 preferable, the case definition used could be amended to include only a record of fever within seven
206 days of the record of seizure.

207 The CPRD provides a large, well-defined source population which has been shown to be representative
208 of the age and sex distribution of the UK population [21, 22]. A disadvantage of the CPRD is that

209 seizures may not always be recorded in a patients' general practice record using a relevant Read code
210 when patients with seizures present directly to Accident and Emergency (A&E) services (secondary
211 care). Comparing CPRD incidence rates to those reported in the literature (Table 4) the incidence
212 rates we observed in the CPRD are between 10% and 88% lower than those observed in prospective
213 follow-up studies [20, 23, 24] and electronic health record studies in the Danish National Hospital
214 Register [11, 16] that all included A&E data. The exception is a third Danish study, which also used the
215 Danish National Hospital Register (but only included primary discharge diagnoses) [25]. This illustrates
216 the importance of understanding the methods used to produce the rates. The impact of A&E events
217 is most evident in the VAESCO [16] data that used standardized methodology across several European
218 electronic health record databases and shows a markedly higher incidence in the Danish data source
219 that included A&E data.

220 In future, ascertainment of seizure events on the CPRD might be improved through linkage with
221 Hospital Episode Statistics (HES) data; however the quality of HES A&E data remains questionable [26].
222 In the absence of such linkage, an alternative option to increase the ascertainment of seizures
223 presenting in secondary care would be to search the free text associated with Read codes such as
224 "discharge summary", "hospital discharge letter" or "Seen in A&E" for key words related to a seizure.
225 This would allow for the identification of events in which the general practice has been informed of
226 event occurrence but has recorded the event in the free text associated with a non-seizure diagnostic
227 code rather than using a seizure specific code.

228 False positive outcome misclassification may also have occurred in this study, for example if diagnostic
229 codes for seizure had been used to record follow up consultations about an earlier recorded seizure
230 episode. While we have not formally investigated the extent of positive or negative misclassification,
231 overall, we expect the magnitude of false negative misclassification to outweigh any false positive
232 misclassification and therefore suggest that our rates be assumed to under-estimate the true rate of
233 seizures in the population. Additionally, the event dates used in this study may reflect the date an

234 event was recorded in the database rather than the date of event occurrence; this may have a small
235 impact on our age and calendar year specific rates.

236 In observed vs expected calculations the number of subjects exposed to the vaccine is often the least
237 accurate of the inputs, and similarly the results are generally more sensitive to the risk window
238 selected than to variations in the background rate. Nevertheless it is important to select the most
239 accurate background rate available. If the required age strata are available from a data source in a
240 different geographic region which includes A&E events then using these as inputs would be preferable
241 to using a geographically accurate source which lacks A&E events as Table 3 shows less variation due
242 to geography (within Europe) than to inclusion of A&E events.

243 However, given the variation observed in incidence rates across age strata it is important that
244 appropriate consideration be given to which is the most comparable age stratum to use. However, the
245 specific age stratum of interest is often unlikely to be available in the literature. The interactive
246 spreadsheet we provide in Supplementary File 3 should allow the reader to obtain incidence rates and
247 expected numbers of events for the stratum that is most comparable to the one from which their
248 observed events are derived; it also allows sensitivity analyses assuming a level of underestimation,
249 whereby the reader can specify a percentage of seizures they assume the CPRD has missed when
250 calculating expected numbers of events. Such a resource should prove useful in future studies
251 reporting background incidence rates for use in post-marketing surveillance.

252 *Conclusions*

253 The results reported in this study provide reference or background incidence rates that can be used
254 in the postmarketing surveillance of vaccines and other products with the potential to cause seizures.
255 However, given the potential for underascertainment of seizure events, and the variation observed
256 across age strata, care must be taken when interpreting and using these rates.

257

258 **Authorship**

259 CJS, RAC and JGW designed the study, CJS and JS extracted and analysed the data, CJS drafted the
260 manuscript, RAC, JGW and JS revised the manuscript for important intellectual content. CJS, RAC, JS
261 and JGW read and approved the final manuscript submitted for publication.

262

263

264 **Acknowledgements**

265 This study is based in part on data from the Full Feature General Practice Research Database (now
266 termed Clinical Practice Research Database) obtained under licence from the UK Medicines and
267 Healthcare Products Regulatory Agency. However, the interpretation and conclusions contained in
268 this study are those of the authors alone. The authors would like to acknowledge the valuable
269 contribution of Professor Corinne de Vries in the early stages of this study.

270 **Conflict of interest**

271 This study was funded by Novartis Vaccines and Diagnostics S.r.l., study number V72_630BTP. The
272 author affiliated with Novartis Vaccines and Diagnostics S.r.l. was involved in study design and
273 preparation of the manuscript. However, this study does not evaluate the safety of any products.

274 **Ethical Statement**

275 The GPRD has a single Multi-Centre Ethics approval for all observational studies using GPRD data
276 (Trent MREC, ref: 05/MRE04/87). The extraction and analysis of the data used in this study has been
277 approved by the Independent Scientific Advisory Committee of the CPRD under approval number
278 10_057.

279

- 280 [1] Bonhoeffer J, Menkes J, Gold MS, de Souza-Brito G, Fisher MC, Halsey N, et al. Generalized
281 convulsive seizure as an adverse event following immunization: case definition and
282 guidelines for data collection, analysis, and presentation. *Vaccine* 2004;22(5–6):557-62.
- 283
284 [2] National Institutes of Health. (2012) Medline Plus - Seizures.
285 Available:<http://www.nlm.nih.gov/medlineplus/ency/article/003200.htm>. Accessed
286 17/09/2013.
- 287
288 [3] Freeman JM. Consensus statement--febrile seizures: a consensus of their significance,
289 evaluation, and treatment. *Bol Asoc Med P R* 1981;73(2):82.
- 290
291 [4] Verity CM, Butler NR, Golding J. Febrile convulsions in a national cohort followed up from
292 birth. I--Prevalence and recurrence in the first five years of life. *Br Med J (Clin Res Ed)*
293 1985;290(6478):1307-10.
- 294
295 [5] Annegers JF, Rocca WA, Hauser WA. Causes of epilepsy: contributions of the Rochester
296 epidemiology project. *Mayo Clin Proc* 1996;71(6):570-5.
- 297
298 [6] Vestergaard M, Obel C, Henriksen TB, Christensen J, Madsen KM, Ostergaard JR, et al. The
299 Danish National Hospital Register is a valuable study base for epidemiologic research in
300 febrile seizures. *J Clin Epidemiol* 2006;59(1):61-6.
- 301
302 [7] Waruiru C, Appleton R. Febrile seizures: an update. *Archives of Disease in Childhood*
303 2004;89(8):751-6.
- 304
305 [8] Berg AT, Shinnar S, Darefsky AS, Holford TR, Shapiro ED, Salomon ME, et al. Predictors of
306 recurrent febrile seizures. A prospective cohort study. *Arch Pediatr Adolesc Med*
307 1997;151(4):371-8.
- 308
309 [9] Offringa M, Bossuyt PMM, Lubsen J, Ellenberg JH, Nelson KB, Knudsen FU, et al. Risk-Factors
310 for Seizure Recurrence in Children with Febrile Seizures - a Pooled Analysis of Individual
311 Patient Data from 5 Studies. *J Pediatr* 1994;124(4):574-84.
- 312
313 [10] Barlow WE, Davis RL, Glasser JW, Rhodes PH, Thompson RS, Mullooly JP, et al. The Risk of
314 Seizures after Receipt of Whole-Cell Pertussis or Measles, Mumps, and Rubella Vaccine. *New*
315 *England Journal of Medicine* 2001;345(9):656-61.
- 316
317 [11] Sun Y, Christensen J, Hviid A, et al. Risk of febrile seizures and epilepsy after vaccination with
318 diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and haemophilus influenzae
319 type b. *JAMA* 2012;307(8):823-31.
- 320
321 [12] Australian Therapeutic Goods Administration (TGA). (2010) Investigation into febrile
322 reactions in young children following 2010 seasonal trivalent influenza vaccination.

323 Available:<http://www.tga.gov.au/pdf/alerts-medicine-seasonal-flu-100702.pdf>. Accessed
324 17/09/2013.

325

326 [13] Black S, Eskola J, Siegrist CA, Halsey N, Macdonald N, Law B, et al. Importance of background
327 rates of disease in assessment of vaccine safety during mass immunisation with pandemic
328 H1N1 influenza vaccines. *Lancet* 2009;374(9707):2115-22.

329

330 [14] Kurz X, Domergue F, Slattery J, Segec A, Szmigiel A, Hidalgo-Simon A. Safety monitoring of
331 Influenza A/H1N1 pandemic vaccines in EudraVigilance. *Vaccine* 2011;29(26):4378-87.

332

333 [15] Wijnans L, Lecomte C, de Vries C, Weibel D, Sammon C, Hviid A, et al. The incidence of
334 narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and
335 vaccination campaigns. *Vaccine* 2013;31(8):1246-54.

336

337 [16] VAESCO. (2013) BACKGROUND RATES. Available:[http://vaesco.net/vaesco/results/BGR-
338 2010.html](http://vaesco.net/vaesco/results/BGR-2010.html). Accessed 05/03/2014.

339

340 [17] Williams T, van Staa T, Puri S, Eaton S. Recent advances in the utility and use of the General
341 Practice Research Database as an example of a UK Primary Care Data resource. *Therapeutic
342 Advances in Drug Safety* 2012;3(2):89-99.

343

344 [18] Wood L, Martinez C. The general practice research database: role in pharmacovigilance.
345 *Drug Saf* 2004;27(12):871-81.

346

347 [19] Consensus statement. Febrile seizures: long-term management of children with fever-
348 associated seizures. *Pediatrics* 1980;66(6):1009-12.

349

350 [20] Van den Berg BJ, Yerushalmy J. Studies on Convulsive Disorders in Young Children. *Pediatr
351 Res* 1969;3:298-304.

352

353 [21] Campbell J, Dedman DJ, Eaton SC, Gallagher AM, Williams TJ. Is the CPRD GOLD Population
354 Comparable to the U.K. Population? *Pharmacoepidemiology and Drug Safety*
355 2013;22(S1):280.

356

357 [22] Mathur R, Bhaskaran K, Chaturvedi N, Leon DA, Vanstaa T, Grundy E, et al. Completeness
358 and usability of ethnicity data in UK-based primary care and hospital databases. *J Public
359 Health (Oxf)* 2013.

360

361 [23] Sillanpaa M, Camfield P, Camfield C, Haataja L, Aromaa M, Helenius H, et al. Incidence of
362 febrile seizures in Finland: prospective population-based study. *Pediatr Neurol*
363 2008;38(6):391-4.

364

365 [24] Verburgh ME, Bruijnzeels MA, van der Wouden JC, van Suijlekom-Smit LW, van der Velden J,
366 Hoes AW, et al. Incidence of febrile seizures in The Netherlands. Neuroepidemiology
367 1992;11(4-6):169-72.

368
369 [25] Rasmussen TA, Jorgensen MR, Bjerrum S, Jensen-Fangel S, Stovring H, Ostergaard L, et al.
370 Use of population based background rates of disease to assess vaccine safety in childhood
371 and mass immunisation in Denmark: nationwide population based cohort study. BMJ
372 2012;345:e5823.

373
374 [26] Health and Social Care Information Centre. (2014) Accident and Emergency Attendances in
375 England - 2012-13. Available:<http://www.hscic.gov.uk/catalogue/PUB13464>. Accessed
376 05/03/2014.

377

378

379

380 .

381

Author final version

382

383

384

Table 1. Age category specific rates of febrile seizure, afebrile seizure and generalised convulsive seizure (GCS). Includes all events occurring in the study population during follow up (i.e. multiple events per individual included)

Age category (months)	All events								
	GCS			Febrile			Afebrile		
	n	IR	CI ₉₅	n	IR	CI ₉₅	n	IR	CI ₉₅
2-12	4768	8.34	(8.11-8.58)	3174	5.56	(5.37-5.75)	1595	2.79	(2.66-2.93)
13-24	10341	16.63	(16.31-16.95)	8550	13.77	(13.48-14.07)	1793	2.88	(2.75-3.02)
25-60	9933	6.13	(6.01-6.25)	6838	4.23	(4.13-4.33)	3097	1.91	(1.85-1.98)
61-120	3290	1.95	(1.88-2.02)	966	0.58	(0.54-0.61)	2324	1.38	(1.32-1.43)
121-180	585	1.41	(1.29-1.52)	94	0.23	(0.18-0.28)	491	1.18	(1.08-1.29)

385

386

387

Table 2. Age category specific rates of *first* febrile seizure, afebrile seizure and generalised convulsive seizure (GCS). Includes only the first event per individual during follow up (i.e. multiple events per individual not included).

Age category (months)	First events only								
	GCS			Febrile			Afebrile		
	n	IR	CI ₉₅	n	IR	CI ₉₅	n	IR	CI ₉₅
2-12	3659	6.42	(6.21-6.63)	2669	4.68	(4.50-4.86)	1105	1.93	(1.82-2.05)
13-24	7232	11.76	(11.49-12.03)	6386	10.38	(10.13-10.63)	1145	1.85	(1.74-1.96)
25-60	5502	3.46	(3.37-3.55)	4280	2.69	(2.61-2.67)	1689	1.05	(1.00-1.10)
61-120	1637	0.99	(0.94-1.04)	609	0.37	(0.34-0.40)	1243	0.74	(0.70-0.78)
121-180	306	0.75	(0.67-0.84)	71	0.17	(0.14-0.22)	265	0.64	(0.57-0.72)

388

389
390
391
392
393
394
395

Table 3 Proportion of febrile seizures identified using different case identification methods

Identification method	N cases	% total
Read code for Febrile Seizure	15,733	(80.1)
Read code for seizure and Read code for fever or febrile seizure code within 7 days	600	(3.1)
Read code for seizure and Read code for fever or febrile seizure code within 14 days	152	(0.8)
Read code for seizure and free text containing a string related to fever* within 7days	2,830	(14.4)
Read code for seizure and free text containing a string related to fever* within 14 days	307	(1.6)
Febrile seizures	19622	(100)

*Text strings related to fever include “*fever*”, “*febrile*”, “*pyrex*”, “*temp*”

396
397
398

Table 4. Comparison with the literature

Study	Period children born in	Country	A&E ^a	First/All events	Study perspective	Age (months old)	Outcome ^b	IR (per 1000PY)	Equivalent CPRD IR ^c
Electronic health record studies									
VAESCO [16]	1993-<2009	UK	No	All ^d	Retrospective	0-59	GCS	7.4	9.0
VAESCO [16]	1991-<2008	Netherlands	No	All ^d	Retrospective	0-59	GCS	7.8	9.0
VAESCO [16]	1993-<2009	Spain	No	All ^d	Retrospective	0-59	GCS	5.0	9.0
VAESCO [16]	1999-<2008	Finland	No	All ^d	Retrospective	0-59	GCS	8.9	9.0
VAESCO [16]	1996-<2009	Italy	No	All ^d	Retrospective	0-59	GCS	9.1	9.0
VAESCO [16]	1995-<2009	Norway	No	All ^d	Retrospective	0-59	GCS	6.6	9.0
VAESCO [16]	1992-<2008	Sweden	No	All ^d	Retrospective	0-59	GCS	4.5	9.0
VAESCO [16]	1991-<2009	Denmark	Yes	All ^d	Retrospective	0-59	GCS	14.4	9.0
Sun <i>et al</i> [11]	2003-<2009	Denmark	Yes	First	Retrospective	3-17	FS	17.2	7.3
Rasmussen <i>et al</i> [25]	1980-<2010	Denmark	Yes	First ⁱ	Retrospective	12-47	FS	5.9	6.1
Follow up studies									
Van den Berg <i>et al</i> [20]	1960-<1968	USA	Yes	First	Prospective	0-59	GCS	6.5	6.0
							FS	4.6	4.9
							AFS	1.8	1.4
Vestergaard <i>et al</i> [6]	1990-<1992	Denmark	Yes ^f	First	Retrospective	3-59	FS	4.9%^g	2.2%
Verity <i>et al</i> [4]	1970- <1971 ^h	UK	Yes ^f	First	Retrospective	0-59	FS	2.3%^g	2.2%
Sillanpaa <i>et al</i> [23]	1986-<1987	Finland	Yes ^f	All	Prospective	0-59	FS	14	6.7
Annegers <i>et al</i> [5]	1935-<1985	USA	Yes	First	Retrospective	0-59	FS	2.0% ^g	2.2%
Verburgh <i>et al</i> [24]	1982-<1988	Netherlands	No	First	Prospective	2-59	FS	5.5	4.9

^a A&E = Accident and Emergency ^b GCS = Generalised convulsive seizures, FS = Febrile seizures, AFS = afebrile seizure ^c Rates observed for similar outcome/age band in current study, however where rates in literature included events occurring before 2 months of age the CPRD rate will not. ^d in the VAESCO study recurrent events within 2 weeks of a first event were excluded. ^e Data collected through parental interview therefore A&E events assumed to be included ^f Incidence rate not available for these studies, prevalence shown instead, and CPRD prevalence for comparison is calculated among subset of individuals with complete follow up from 2 months up to 5 years of age (n= 237,832, ~20% of total study population). ^h Verity *et al* included children born in a single week in April 1970. ⁱ Only primary discharge diagnoses included.

401

402

403

404 **Figure 1** Incidence of febrile, afebrile and generalised convulsive seizures by month of age.

405

406

407

408 Figure 2 Incidence of *first* febrile, afebrile and generalised convulsive seizures by month of age.

409

Author final version